Author name: Leonardo Arias

It’s another prong in the agency’s digital health modernization project, which has faced setbacks and delays.

Analysts called the acquisition a good fit for Axogen but said the company’s plans to finance the deal with a public stock offering could be a point of contention for investors.

CFO Preston Wells said at a healthcare conference that the company is still working through supply issues in its peripheral vascular business and had fewer hip sales than expected so far this quarter.

The CMS released draft star ratings, including the thresholds for reaching those ratings, to plans earlier this week. The grading sheet got stricter, which doesn’t bode well for insurers, one MA expert said.

The company promoted three executives and eliminated a fourth position as part of changes intended to support its ongoing commercial transformation.

Health Catalyst has cycled through three CEOs in eight months. The data analytics company is betting its newest chief can navigate an AI pivot and revenue headwinds.

Nearly half of U.S. hospitals are now without obstetric services, according to a new report, and closures could worsen as Medicaid cuts threaten hospital finances.

With multiple drug pricing initiatives like Most Favored Nation now in force, drugmakers have to reinvent their commercial strategies to stay ahead of the fast-moving policy environment, according to a new report from Numerof & Associates.

The enrollment pause comes after BHV-7000 failed to show efficacy in a midstage depression trial late last year. The news is another regulatory hit for Biohaven after the FDA declined to approve its spinocerebellar ataxia treatment in November 2025.

Despite falling short of analyst expectations, Tyra Biosciences is taking its cancer drug to registrational development for non-muscle invasive bladder cancer.